The goal of the workshop No Stone Unturned: The Relentless Pursuit of a Cure for Glioblastoma, is to inspire and support breakthrough science in glioblastoma research and to accelerate the development of new therapies. The Mark Foundation, the Sontag Foundation, and a coalition of funders of cancer research invite workshop attendees to submit a Letter of Intent under a unique request for proposals through The Mark Foundation’s ASPIRE Award and Endeavor Award funding mechanisms.
Successful proposals will pick up on themes and ideas developed at and inspired by the workshop, and/or to progress the development of innovative and effective glioblastoma therapies.
ASPIRE Award:
The letter of intent can be a maximum of 2 pages, including any references, figures, or tables. The PDF must contain the following information:
Endeavor Award:
The application process will begin with a letter of intent stage consisting of a 2-page description of the project. The portal for the letter of intent is now open and letters are due on January 8, 2025. Invitations for full applications will be issued in March 2025.
Thursday, November 14th, 2024: Letter of intent portal opens
Wednesday, January 8th, 2025: Letter of intent submission deadline
March 2025: Invitations for full application
September 2025: Anticipated award start
ASPIRE Awards are designed to enable innovative approaches to solving high-impact problems in cancer research. These awards will be used to support high-risk, high-reward projects with research plans designed to answer key feasibility and proof-of-concept questions in an accelerated, one-year period. Projects that successfully demonstrate feasibility may be selected to apply for additional funding in a second phase to further develop their innovative concepts.
Endeavor Awards support collaborative research projects that bring together investigators with diverse areas of expertise to tackle challenges in the prevention, diagnosis, and treatment of cancer. These grants are awarded to teams of three or more investigators to generate and integrate data from diverse lines of research and transform those insights into advances for cancer patients that could not be achieved by individual efforts.